Revolution Medicines, Inc.
RVMD
$39.13
$0.010.03%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -97.16% | -97.49% | -86.89% | -67.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -97.16% | -97.49% | -86.89% | -67.27% |
| Cost of Revenue | 46.66% | 67.35% | 76.80% | 39.34% | 26.80% |
| Gross Profit | -52.15% | -86.54% | -104.97% | -58.38% | -42.09% |
| SG&A Expenses | 55.95% | 60.54% | 59.95% | 60.00% | 52.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.70% | 59.07% | 63.76% | 71.43% | 61.16% |
| Operating Income | -49.35% | -70.15% | -78.54% | -91.44% | -78.76% |
| Income Before Tax | -36.59% | -69.00% | -76.21% | -87.92% | -76.57% |
| Income Tax Expenses | 78.63% | 108.60% | -739.05% | -739.05% | -739.05% |
| Earnings from Continuing Operations | -37.52% | -71.14% | -75.27% | -86.87% | -75.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.52% | -71.14% | -75.27% | -86.87% | -75.46% |
| EBIT | -49.35% | -70.15% | -78.54% | -91.44% | -78.76% |
| EBITDA | -49.56% | -70.71% | -79.27% | -92.46% | -79.56% |
| EPS Basic | 5.49% | -10.04% | -16.27% | -23.63% | -21.72% |
| Normalized Basic EPS | 1.99% | -2.75% | -10.85% | -18.03% | -16.78% |
| EPS Diluted | 5.49% | -10.04% | -16.27% | -23.63% | -21.72% |
| Normalized Diluted EPS | 1.99% | -2.75% | -10.85% | -18.03% | -16.78% |
| Average Basic Shares Outstanding | 48.29% | 59.43% | 54.51% | 52.21% | 40.28% |
| Average Diluted Shares Outstanding | 48.29% | 59.43% | 54.51% | 52.21% | 40.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
